JAIDS Journal of Acquired Immune Deficiency Syndromes, Journal Year: 2023, Volume and Issue: 94(3), P. e5 - e8
Published: Oct. 18, 2023
Stenberg, Erik MD, PhDa; Carlander, Christina PhDb,c; Cao, Yang PhDd,e; Ottosson, Johan Näslund, PhDf Author Information
Language: Английский
Expert Review of Clinical Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 8
Published: Jan. 31, 2025
Introduction Medication management after bariatric surgery is a major and complex challenge. The altered gastrointestinal anatomy/physiology post-surgery may impact oral drug absorption/pharmacokinetics, with potential clinical implications. Along multiple studies/cases of impaired leading to treatment failure, reports increased exposure, post-bariatric safety issues adverse effects risk, are also available; yet, this second scenario levels, less familiar in practice.
Language: Английский
Citations
1
Current Nutrition Reports, Journal Year: 2023, Volume and Issue: 12(4), P. 695 - 708
Published: Oct. 20, 2023
Abstract Purpose of Review Obesity constitutes a major public health concern and has been recognized as an epidemic. To date, bariatric surgery remains the most effective way for substantial long-lasting weight loss in severe obesity. The purpose this review is to summarize how pharmacokinetics drugs are affected by common types surgery, i.e., Roux-en-Y gastric bypass (RYGB) sleeve gastrectomy (SG). Recent Findings Limited data available regarding changes after surgery. lack existing guidelines may lead patients experience drug toxicity or therapeutic undertreatment. Pharmacokinetic parameters that need be taken into consideration postoperatively include motility, volume, pH, surface area, bile secretions, carrier proteins, first-pass metabolism. For with narrow index, other factors monitored closely, including plasma levels, patients’ clinical outcomes, laboratory markers. Patients should followed up frequently treated accordance their response therapy. Summary Bariatric affect various drugs, due resultant anatomical loss. Therefore, there identify those potential adjust medication doses order achieve higher efficacy avoid toxicity.
Language: Английский
Citations
16
International Journal of Pharmaceutics, Journal Year: 2023, Volume and Issue: 645, P. 123347 - 123347
Published: Aug. 24, 2023
Language: Английский
Citations
10
Expert Review of Clinical Pharmacology, Journal Year: 2024, Volume and Issue: 17(7), P. 579 - 587
Published: June 3, 2024
Introduction The treatment of HIV infection has been revolutionized in recent years thanks to the advent dual antiretroviral regimens, administered orally or as long-acting injectable formulations. Here, we provide an update on usefulness therapeutic drug monitoring (TDM) drugs optimize management people with (PWH) current scenario.
Language: Английский
Citations
4
HIV Medicine, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 15, 2025
To measure concentrations of tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) among individuals taking disoproxil fumarate plus emtricitabine (TDF/FTC) or alafenamide (TAF/FTC) who were scheduled to undergo had already undergone bariatric surgery. We enrolled pre-exposure prophylaxis (PrEP) users attending clinics Toronto Ottawa undergoing After participants completed a minimum 7 days consecutive PrEP dosing, we collected DBS samples immediately before they administered their next daily dose PrEP. Participants surgery enrolment provided single sample at baseline only. One participant planned preoperatively and on postoperative 7, 28 84. TFV-DP was measured by liquid chromatography tandem mass spectrometry. compared results against the population range varying degrees adherence stratified chronology surgery, type regimen. Of seven eligible participants, all gay, cis-gender men. Median age 48 years (Q1-Q3: 44-51). Six underwent enrolment: four Roux-en-Y gastric bypass (RYGB) two sleeve gastrectomy (SG). Four TDF/FTC TAF/FTC. All therapeutic concentrations, except for one SG. TAF/FTC receiving RYGB displayed slight decrease over time, although remained range. Tenofovir near values this small men using oral
Language: Английский
Citations
0
AIDS, Journal Year: 2025, Volume and Issue: 39(5), P. 625 - 626
Published: March 13, 2025
Testa, Jacopo; Cattaneo, Dario; Giacomelli, Andrea; Lai, Alessia; Ridolfo, Anna Lisa; Gori, Menzaghi, Barbara; Gervasoni, Cristina Author Information
Language: Английский
Citations
0
Current HIV/AIDS Reports, Journal Year: 2022, Volume and Issue: 20(1), P. 9 - 18
Published: Nov. 23, 2022
Language: Английский
Citations
14
HIV Medicine, Journal Year: 2023, Volume and Issue: 24(10), P. 1029 - 1034
Published: June 20, 2023
Abstract Background and objectives Obesity trends metabolic dysregulation are rising in people living with HIV using antiretrovirals (ARVs). Underlying causes preventive strategies being investigated. Two glucagon like‐peptide 1 (GLP‐1) agonists, liraglutide semaglutide, were formerly approved as glucose‐lowering drugs have been recently for long‐term weight loss obesity. Due to the lack of therapeutic guidelines or clinical trials HIV, we discuss potential benefits, safety aspects pharmacological considerations prescribing semaglutide HIV. Results Clinical experience is limited two cases diabetic after which a successful glycaemic control observed. None adverse events associated usage indicate an additional risk Extra caution showed be warranted when initiating GLP‐1 agonist therapy taking protease inhibitors who pre‐existing factors heart rate variability reduce incidence RP interval prolongation. agonists metabolized by endopeptidases, thus do not generate major drug–drug interactions most drugs, including ARVs. GLP‐s known inhibit gastric acid secretion, warrants close monitoring combined atazanavir oral rilpivirine, ARVs that require low pH optimal absorption. Conclusion Theoretical few available observations support prescription with, far, no indications concern regarding efficacy,
Language: Английский
Citations
7
Clinical Infectious Diseases, Journal Year: 2023, Volume and Issue: 77(11), P. 1561 - 1568
Published: June 30, 2023
Abstract Background The implications of bariatric surgery (BS) on virologic and metabolic outcomes in people with human immunodeficiency virus (HIV; PWH) antiretroviral therapy (ART) are unknown. Methods Here, we report a retrospective analysis up to 18 months post-BS PWH from the AIDS Therapy evaluation Netherlands (ATHENA) cohort data all dutch HIV treating Centers. Primary end points were confirmed failure (2 consecutive HIV-RNA measurements >200 copies/mL) percentage patients who achieved >20% total body weight loss post-BS. Switches baseline ART trough plasma concentrations antiretrovirals also reported Metabolic parameters medication usage compared pre- Results Fifty-one included. One case 3 cases viral blips detected this Eighty-five percent at post-BS, mean difference (95% confidence interval) −33.5% (−37.7% −29.3%). Trough measured agents above minimum effective concentrations, except for 1 sample darunavir. Lipid profiles, but not serum creatinine blood pressure, improved significantly (P < .01) Total medications obesity-related comedications declined 203 103 62 25, respectively, Conclusions BS was an intervention lipid control using no clear link poor outcomes.
Language: Английский
Citations
4
Obesity Surgery, Journal Year: 2024, Volume and Issue: 34(10), P. 3594 - 3605
Published: Aug. 27, 2024
Individuals with human immunodeficiency virus (HIV) infection now have life expectancies similar to non-infected people but face increased obesity prevalence. The long-term effects of bariatric surgery (BS) and conservative weight therapy (CWT) in patients living HIV (PLWH) remain unexplored.
Language: Английский
Citations
0